BIEL Corporation’s Revival: The Spark That Ignites Viant’s Profit Engine
The official revival of BioElectronics Corp. (BIEL) in Maryland marks a pivotal moment—not just for the company, but for Viant Medical and any private entity eyeing public market leverage. This isn’t just a corporate update—it’s the ignition point for a high-octane financial strategy built on equity arbitrage, tax efficiency, and medtech innovation.
BIEL’s Revival = Viant’s Launchpad
With BIEL now officially active again, the strategic thesis becomes actionable:
Public Market Access: BIEL’s OTC status offers Viant instant entry into public markets—no IPO, no SPAC, no friction.
Share Accumulation at Historic Lows: PPS at $0.0001–$0.0002 means Viant can scoop up 1B+ shares for ~$200K.
Revived Entity = Renewed Momentum: Regulatory filings, board appointments, and product expansion are now back on the table.
The Math Behind the Windfall
Let’s break it down:
$400K quarterly revenue = PPS $0.01
$10M annual profit (with VA adoption and RecoveryRX Veterinary) = PPS $0.04
Full U.S. insurance reimbursement = PPS $0.25–$0.40
Tax Exposure: $0 (BIEL has up to $40M profit shield)
This is not speculative fluff—it’s a structured arbitrage model with asymmetric upside.
Strategic Synergy: Viant + BIEL
Tech Modernization: Viant’s infrastructure can fast-track RecoveryRx’s mobile integration and global rollout.
Regulatory Acceleration: Viant’s ISO/Class I–III expertise can push BIEL into broader FDA and insurance territory.
Revenue Multiplication: $400K in quarterly revenue could push PPS to $0.01—Viant’s equity stake balloons accordingly.
Why This Is the Ground-Floor Moment
BIEL is revived and active—no longer a dormant shell.
Products are FDA-cleared, scientifically validated, and aligned with global health mandates.
Viant has board-level influence and operational synergy.
The public equity vehicle is live, liquid, and undervalued.
Final Thought: The Bitcoin Treasury Playbook—But Better
Instead of holding volatile crypto, Viant holds a real company with:
FDA-cleared products
Revenue-generating operations
Tax-shielded profits
Public market leverage
This is PPS leverage as a balance sheet weapon. BIEL’s revival isn’t just a corporate update—it’s the green light for Viant’s profit windfall.
The official revival of BioElectronics Corp. (BIEL) in Maryland marks a pivotal moment—not just for the company, but for Viant Medical and any private entity eyeing public market leverage. This isn’t just a corporate update—it’s the ignition point for a high-octane financial strategy built on equity arbitrage, tax efficiency, and medtech innovation.
BIEL’s Revival = Viant’s Launchpad
With BIEL now officially active again, the strategic thesis becomes actionable:
Public Market Access: BIEL’s OTC status offers Viant instant entry into public markets—no IPO, no SPAC, no friction.
Share Accumulation at Historic Lows: PPS at $0.0001–$0.0002 means Viant can scoop up 1B+ shares for ~$200K.
Revived Entity = Renewed Momentum: Regulatory filings, board appointments, and product expansion are now back on the table.
The Math Behind the Windfall
Let’s break it down:
$400K quarterly revenue = PPS $0.01
$10M annual profit (with VA adoption and RecoveryRX Veterinary) = PPS $0.04
Full U.S. insurance reimbursement = PPS $0.25–$0.40
Tax Exposure: $0 (BIEL has up to $40M profit shield)
This is not speculative fluff—it’s a structured arbitrage model with asymmetric upside.
Strategic Synergy: Viant + BIEL
Tech Modernization: Viant’s infrastructure can fast-track RecoveryRx’s mobile integration and global rollout.
Regulatory Acceleration: Viant’s ISO/Class I–III expertise can push BIEL into broader FDA and insurance territory.
Revenue Multiplication: $400K in quarterly revenue could push PPS to $0.01—Viant’s equity stake balloons accordingly.
Why This Is the Ground-Floor Moment
BIEL is revived and active—no longer a dormant shell.
Products are FDA-cleared, scientifically validated, and aligned with global health mandates.
Viant has board-level influence and operational synergy.
The public equity vehicle is live, liquid, and undervalued.
Final Thought: The Bitcoin Treasury Playbook—But Better
Instead of holding volatile crypto, Viant holds a real company with:
FDA-cleared products
Revenue-generating operations
Tax-shielded profits
Public market leverage
This is PPS leverage as a balance sheet weapon. BIEL’s revival isn’t just a corporate update—it’s the green light for Viant’s profit windfall.
1
